In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

As the Trump administration makes cuts to federal health agencies, some Alzheimer's experts are worried about the impact on ...

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

Alzheimer’s disease is notorious for robbing individuals of memory and cognitive function. Researchers have struggled for ...

Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say ...

Experimental drug NU-9—a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials ...

Susan Aaron was an active 74-year-old retiree with Alzheimer’s who was told she might experience extreme fatigue and terrible headaches if she tried a new drug from Eisai Co. that promised to ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

W ith two new treatments for Alzheimer’s disease approved in recent years, there’s growing hope for people at risk of the ...